tbuckley/cabot-search huggingface dataset:
Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers.
Authors: F Verra, E Escudier, F Lebargy, J F Bernaudin, H De Crémoux, J Bignon
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Although respiratory changes induced by tobacco smoke have been extensively described, no study has focused on ciliary abnormalities associated with chronic smoking. Ciliary ultrastructure was studied in 37 adults with chronic sputum production (CSP) consisting of 13 current smokers (Group 1), 5 ex-smokers (Group 2), and 19 nonsmokers (Group 3). Five healthy nonsmokers constituted the control group (Group 4). Clinical and radiologic data and respiratory function tests were recorded. Acute respiratory infection was diagnosed by culture of tracheobronchial secretions obtained during bronchoscopy. Bronchial ciliated cells were obtained and processed for transmission electron microscopy. Within each group, the percentages of abnormal cilia were similar in patients with either chronic bronchitis or bronchiectasis and in patients with or without acute infection. The percentage of axonemal ultrastructural abnormalities (AUA) was higher in smokers (16.5% +/- 2.7%) and ex-smokers (17.5% +/- 7%) than in nonsmokers (5.2% +/- 1%) or control subjects (0.7% +/- 0.2%) (p < 0.0002). The AUA were polymorphic, characteristic of acquired ultrastructural changes. These results suggest that chronic smoking may induce an increased number of abnormal cilia which could participate in impairment of tracheobronchial clearance and which appears to be independent of the etiology of CSP.
Abstract 16237: Predicting Long-term Prognosis in Stable Peripheral Artery Disease With Baseline Functional Capacity Estimated by the Duke Activity Status Index
Authors: Vichai Senthong, Yuping Wu, Stanley Hazen, Wilson Tang
Journal: Circulation (2015)

Introduction: The ability of a simple self-assessment tool for estimated functional capacity to predict long-term prognosis in patients with established peripheral artery disease (PAD) is unknown. Objective: This study examined whether subjective measurement of functional capacity estimated by using of the Duke Activity Status Index (DASI) questionnaire predicts long-term prognosis in patients with established PAD. Methods: We examined the relationship between DASI scores and all-cause mortality over a 5-year follow-up in 771 stable patients with established PAD. Results: Two hundred ten patients (27%) died over 5-year follow-up . The lowest DASI scores were associated with a 3.2-fold increased risk of 5-year all-cause mortality (HR 3.23, 95%CI 2.19-4.75, p&lt;0.001; Figure). For overall PAD patients, after adjustments for traditional risk factors, estimated glomerular filtration rate (eGFR), high-sensitivity C-reactive protein (hsCRP), and low DASI score remained predictive of 5-year all-cause mortality (adjusted HR 2.09, 95%CI 1.36-3.23, p&lt;0.001). Adjusting for traditional risk factors, eGFR and hsCRP, patients with the lowest DASI scores had higher 5-year all-cause mortality (HR 2.13, 95%CI 1.1-4.12, p&lt;0.05 for carotid artery stenosis (CAS); HR 2.06, 95%CI 1.16-3.64, p&lt;0.05 for non-CAS; HR 2.01, 95%CI 1.11-3.66, p&lt;0.05 for lower extremity artery stenosis (LEAD); and HR 2.15, 95%CI 1.13-4.09, p&lt;0.005 for non-LEAD, respectively). Conclusions: A simple self-assessment tool of functional capacity provides independent and incremental prognostic for long-term adverse clinical events in stable patients with established PAD beyond each PAD diagnostic subtype.
Transforming growth factor?beta 1 (TGF-?1) and TGF-?1 receptors in normal, cirrhotic, and neoplastic human livers*1
Authors: P BEDOSSA
Journal: Hepatology (1995)

Transforming growth factor-Beta 1 (TGF-β1) is an important mediator of control of liver cell proliferation and replication. The aim of the current study was to compare TGF-β1 gene expression, protein synthesis, and cell membrane receptors in normal liver, cirrhotic nodules, and neoplastic human livers. Five surgical resections for metastasis in an otherwise normal liver and 25 resections for hepatocellular carcinoma with cirrhosis were included in this study. Messenger RNA (mRNA) and TGF-β1 protein were detected on serial tissue sections of normal, cirrhotic, and tumoral livers using in situ hybridization and immunohistochemistry. TGF-β1 type II receptors were detected on tissue sections using immunohistochemistry. In normal livers, TGF-β1 mRNA and protein were not significantly expressed. In cirrhotic nodules, a few sinusoidal cells and mesenchymal cells of fibrous septa displayed TGF-β1 mRNA. By immunohistochemistry, protein was detected in the extracellular matrix along the fibrous septa. Hepatocytes from normal and cirrhotic livers did not express TGF-β1. In contrast, the cytoplasm of hepatocytes in neoplastic nodules showed intense staining for TGF-β1 mRNA and protein. Although TGF-β1 receptor II was expressed on the plasma membrane of normal liver cells, tumoral hepatocytes no longer displayed membrane labeling but rather diffuse intracytoplasmic staining with perinuclear accumulation. This study suggests that the escape of tumoral hepatocytes from control of cell proliferation by TGF-β1, despite its overexpression by these cells, might be related to a defect in TGF-β1 receptor II processing on the liver cell membrane.
Prolonged mechanically assisted ventilation. An analysis of outcome and charges
Authors: H. Davis
Journal: JAMA (1980)

Mechanically assisted ventilation is frequently used, but there are little data regarding cost and long-term outcome. Therefore, all patients who required mechanical ventilation for 48 hours or more were studied, their hospitalization charges analyzed, and the survivors observed for two years after discharge. The mean charge for the hospitalization was $12,300, compared with $1,600 for all other hospitalized patients. Although the overall mortality at discharge was 56%, the patients with pulmonary disease had the lowest mortality (29%) with the lowest cost at time of discharge. The mortality for the postoperative and miscellaneous medical group of patients demonstrated no significant increase during the period following discharge, unlike the cardiac and pulmonary groups, whose mortality increased each year of follow-up. Hospitalization for these patients was eight times as costly as for all other hospitalized patients during the same 12 months, with a two-year mortality of 72%. (<i>JAMA</i>243:43-45, 1980)
THE ETHICS OF EATING.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tobacco Oversight
Authors: Bridget M. Kuehn
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postoperative radiotherapy (PORT) for pathologic N2 non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: A review of the National Cancer Database.
Authors: Cliff Grant Robinson, Aalok Patel, Jeffrey D. Bradley, Saiama Naheed Waqar, Daniel Morgensztern, Maria Quintos Baggstrom, Ramaswamy Govindan, Jennifer Bell, Tracey Guthrie, Graham A. Colditz, Traves Crabtree, Daniel Kreisel, Alexander Sasha Krupnick, G Alexander Patterson, Bryan F Meyers, Varun Puri
Journal: Journal of Clinical Oncology (2014)

7509 Background: Adjuvant chemotherapy confers a 5% overall survival (OS) benefit for NSCLC patients following resection. Historic trials predating widespread use of chemotherapy suggested no OS benefit to PORT for N2 disease, felt to be from competing risks of older RT techniques and subsequent toxicity. We investigated the impact of modern PORT on OS for N2 NSCLC patients treated nationally with surgery and adjuvant chemotherapy. Methods: Patients with pathologic N2 NSCLC who underwent complete (R0) resection and adjuvant chemotherapy from 1998 to 2010 were identified from the National Cancer Database. Only patients for whom complete radiation and chemotherapy details were available were included. Patients were stratified by the use of PORT (≥45 Gy) as coded in the database. A total of 4,585 patients were identified (1,909 PORT, 2,676 no PORT) with a median follow-up of 22 months. The impact of PORT on OS was explored using Cox regression. Results: Patients treated with PORT were slightly younger (median 63.5 vs. 65 years, p<0.001) and healthier (Charlson 0 in 60.8% vs. 55.2%, p<0.001), though less likely to be treated at an academic facility (31.6% vs. 40.9%, p<0.001). Patients treated with PORT had fewer pneumonectomies (5.9% vs. 9.9%, p<0.001) and more sublobar resections (16.3% vs. 9.8%, p<0.001), and slightly smaller tumors (34.6 vs. 36.7 mm, p<0.015). On multivariate analysis, factors independently predictive of improved OS for the entire group were younger age, treatment at an academic facility, higher income, lower Charlson score, smaller tumor, ≥ lobectomy, and use of PORT (HR 0.873, 95% C.I. 0.789-0.965). Use of PORT was associated with a significant increase in median and 5-year overall survival compared to no PORT, 45.9 vs. 40.7 months and 39.1% vs. 34.7% (p=0.005), respectively. Conclusions: For NSCLC patients with N2 disease following complete resection and adjuvant chemotherapy, modern PORT appears to confer an additional 5% survival advantage beyond that achieved with adjuvant chemotherapy alone. Investigators are encouraged to enroll on prospective trials such as LungART, a randomized trial of modern PORT vs no PORT in resected NSCLC.
RATION OF THE UNITED STATES NAVY.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
Authors: N. Wolmark, G. Yothers, M. J. O'Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O'Reilly, C. J. Allegra
Journal: Journal of Clinical Oncology (2009)

LBA4 Background: The primary aim of this two-arm randomized prospective study was to determine whether mFOLFOX6 plus bevacizumab (mFF6+B) would prolong disease-free survival (DFS) compared to mFOLFOX6 (mFF6) alone. Methods: Between September 2004 and October 2006, 2,672 patients with follow-up (1,338 and 1,334 in respective arms) with stage II (24.9%) or III carcinoma of the colon were randomized to receive either mFF6 (oxaliplatin 85 mg/m2 IV d1, leucovorin 400 mg/m2 IV d1, 5-FU 400 mg/m2 IV bolus d1, and 5-FU 2400 mg/ m2 CI over 46 hrs (d1+2) q14d × 12 cycles) or mFF6+B (same mFF6 regimen + bevacizumab 5 mg/kg IV q 2 wks × 1 yr). The primary end point was DFS. Events were defined as first recurrence, second primary cancer, or death. Results: The median follow-up for patients still alive was 36 months. The hazard ratio (HR: FF6+B vs. mFF6) was 0.89; 95% CI (0.76=1.04); p=0.15. Data censored at intervals disclosed an initial benefit for bevacizumab that diminished over time: The smoothed estimate of the DFS HR over time indicated that bevacizumab significantly reduced the risk of a DFS event during the interval from 0.5 to 1.0 year. There was no evidence that patients receiving bevacizumab had a worse DFS compared to those receiving mFF6 alone following treatment. Conclusions: The addition of bevacizumab to mFF6 did not result in an overall statistically significant prolongation in DFS. There was a transient benefit in DFS during the one-year interval that bevacizumab was utilized. Consideration may be given to clinical trials assessing longer duration of bevacizumab administration. Supported by PHS grants U10CA-12027, -69974, -37377, and -69651 from the NCI and a grant from Genentech, Inc. N Ev 3yDFS P Yr 1 1.5 2 2.5 3 mFF6 1338 312 75.5 HR 0.60 0.74 0.81 0.85 0.87 mFF6+B 1334 291 77.4 0.15 P 0.0004 0.004 0.02 0.05 0.08 No significant financial relationships to disclose.
Table of Contents
Authors: Christina Wyatt, Marianne Camargo, Steven Coca, Stephanie Caligiuri, Paul Kenny, Raghu Tadagavadi, W Reeves, Daniel Galvan, Farhad Danesh, Tadashi Takeuchi, Hiroshi Ohno, Naoko Satoh-Takayama, Carmen Peralta, Michelle Estrella, Brendan Crawford, Debbie Gipson, Helen Looker, Robert Nelson, Markus Ketteler, Geoffrey Block, Pieter Evenepoel, Masafumi Fukagawa, Charles Herzog, Linda Mccann, Sharon Moe, Rukshana Shroff, Marcello Tonelli, Nigel Toussaint, Marc Vervloet, Mary Open
Journal: Kidney International (2017)
'Atypical' mumps may occur after immunization
Authors: P. Gunby
Journal: JAMA (1980)

When parotitis and aseptic meningoencephalitis appeared among children in a Little Rock, Ark, elementary school district, authorities immediately suspected mumps. Investigation indicated that none of the sick children had been immunized against the infection. The clincher was the isolation of mumps virus from three of the youngsters. However, at the same time, another and more puzzling illness appeared among other children in the district. Symptoms included fever, appetite loss, nausea, malaise, and a 24-hour erythematous papular rash, generalized except for the head, neck, palms, and soles. A University of Arkansas College of Medicine pediatrician who investigated five cases of this puzzling "other" illness has concluded that it is atypical mumps. What makes this conclusion especially interesting is that, unlike their classmates with parotitis or aseptic meningoencephalitis, all five of these children were immunized against mumps long before the other symptoms developed. Terry Yamauchi, MD, who is professor of pediatrics at
Seventh International Meeting of the International Society for Oncodevelopmental Biology and Medicine
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Seventh International Meeting of the International Society for Oncodevelopmental Biology and Medicine Get access JNCI: Journal of the National Cancer Institute, Volume 62, Issue 6, June 1979, Page 1589, https://doi.org/10.1093/jnci/62.6.1589 Published: 01 June 1979
Origins of Human Malaria: Rare Genomic Changes and Full Mitochondrial Genomes Confirm the Relationship of Plasmodium falciparum to Other Mammalian Parasites but Complicate the Origins of Plasmodium vivax
Authors: S. W. Roy, M. Irimia
Journal: Molecular Biology and Evolution (2008)

We wrongly reported a ;100 bp deletion in mitochondrial genomes of some primate malaria parasites.This was due to misinterpretation, by one of us (SWR), of nearly complete genomic sequences in GenBank as truly complete genome sequences.Our finding regarding the evolutionary relationships of P. vivax and closely related species should therefore be disregarded.All other findings remain unaffected.We thank Susan Perkins, as well as Toshiyuki Hayakawa and coauthors, for pointing out our mistake, and apologize for our error.
Passing Stones
Authors: J W Burnside
Journal: Annals of Internal Medicine (1993)

On Being a Doctor15 March 1993Passing StonesJohn W. Burnside, MDJohn W. Burnside, MDUniversity of Texas Southwestern Medical School, Dallas, TX 75235-9005.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-6-199303150-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail An older physician consults a younger colleague for medical care. Having begun his career with good intentions and hard work, the older physician has become bitter because of the constant demands. His colleague encourages him to retire for his health, with surprising consequences.Some doctors practice too long. Some realize it but don't act while others miss the signals, as do their colleagues and friends. I learned that suggesting retirement to a colleague can be as therapeutic as writing a prescription.Some time ago, I had such a doctor as a patient. He had sent me a few patients for ... Author, Article, and Disclosure InformationAffiliations: University of Texas Southwestern Medical School, Dallas, TX 75235-9005.Corresponding Author: John W. Burnside, MD, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-9005. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 March 1993Volume 118, Issue 6Page: 465-466KeywordsFirearm injuriesFoodMedical conditionsMemoryNervesNeurosurgerySleepSteroidsSurgeryTonsils Issue Published: 15 March 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
FRESH AIR FUNDS FOR CITY CHILDREN.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de “Retour vers le futur: EPAGE II” (6 articles), pp. 200
Journal: Endoscopy (2009)

See also: Appropriateness of colonoscopy in Europe (EPAGE II) – Surveillance after polypectomy and after resection of colorectal cancerEndoscopy 2009; 41(03): 209-217DOI: 10.1055/s-0028-1119646 See also: Appropriateness of colonoscopy in Europe (EPAGE II) – Functional bowel disorders: pain, constipation and bloatingEndoscopy 2009; 41(03): 234-239DOI: 10.1055/s-0028-1119625 See also: Appropriateness of colonoscopy in Europe (EPAGE II) – Screening for colorectal cancerEndoscopy 2009; 41(03): 200-208DOI: 10.1055/s-0028-1119626 See also: Appropriateness of colonoscopy in Europe (EPAGE II) – Chronic diarrhea and known inflammatory bowel diseaseEndoscopy 2009; 41(03): 218-226DOI: 10.1055/s-0028-1119627 See also: Appropriateness of colonoscopy in Europe (EPAGE II) – Presentation of methodology, general results, and analysis of complicationsEndoscopy 2009; 41(03): 240-246DOI: 10.1055/s-0028-1119643 See also: Appropriateness of colonoscopy in Europe (EPAGE II) – Iron-deficiency anemia and hematocheziaEndoscopy 2009; 41(03): 227-233DOI: 10.1055/s-0028-1119644